Telix Pharmaceuticals Ltd.’s prostate cancer PET imaging agent Illuccix has been approved by the Danish Medicines Agency.
Hosted on MSN1mon
Healthy Returns: Novo Nordisk's Ozempic faces scrutiny over potential link to rare eye conditionThe Danish Medicines Agency said it has kept close tabs on ... In a statement Monday, Novo Nordisk said after a "thorough evaluation of the studies" and an internal safety assessment, the Danish ...
Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback